Peptide inhibitors of protein kinase C

Details Peptide inhibitors of protein kinase C Peptide inhibitors of protein kinase C

2007-07-16

2010-11-16

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S014800, C530S330000, C530S327000

Reexamination Certificate

active

07833984

ABSTRACT:
PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.

REFERENCES:
patent: 4351829 (1982-09-01), Zetler et al.
patent: 5776685 (1998-07-01), Riedel
patent: 5783405 (1998-07-01), Mochly-Rosen et al.
patent: 5935803 (1999-08-01), Vasquez et al.
patent: 6165977 (2000-12-01), Mochly-Rosen
patent: 6376467 (2002-04-01), Messing et al.
patent: 6395306 (2002-05-01), Cui et al.
patent: 7393835 (2008-07-01), Mochly-Rosen
patent: 7459424 (2008-12-01), Mochly-Rosen
patent: 7507711 (2009-03-01), Mochly-Rosen
patent: 2003/0143656 (2003-07-01), Alessi et al.
patent: 2003/0223981 (2003-12-01), Mochly-Rosen
patent: 2004/0009922 (2004-01-01), Mochly-Rosen
patent: 2005/0215483 (2005-09-01), Mochly-Rosen
patent: 2009/0143293 (2009-06-01), Mochly-Rosen et al.
patent: WO 94/04686 (1994-03-01), None
patent: WO 97/14038 (1997-04-01), None
patent: WO 99/43805 (1999-09-01), None
patent: WO 00/01415 (2000-01-01), None
patent: WO-00/18895 (2000-04-01), None
patent: WO 00/53218 (2000-09-01), None
patent: WO 01/46252 (2001-06-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 02/057413 (2002-07-01), None
Ron, 1995, The Journal of Biochemistry, 270, 24180-24187.
Mochley-Rosen, 1991, The Journal of Biochemistry, 266, 14866-14868.
Chen, 2001, PNAS, 98, 11114-11119.
Aris, 1993, Biochimica et Biophysica Acta, 1174, 171-181.
Aley et al., “Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C.”The Journal of Neuroscience, 20(12): 4680-5 (2000).
Alvarez et al., “Molecular basis for angiotensin II-induced increase of chloride/bicarbonate exchange in the myocardium.”Circulation Research, 89(12):1246-53 (2001).
Banci et al., “Molecular dynamics characterization of the C2 domain of protein kinase Cbeta.”The Journal of Biological Chemistry, 277(15):12988-97 (2002).
Brzoska et al., “The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor.”Proc Natl Acad Sci U S A, 2(17):7824-8 (1995).
Cardone et al.,“Phorbol myristate acetate-mediated stimulation of transcytosis and apical recycling in MDCK cells.”The Journal of Cell Biology, 124(5):717-27 (1994).
Cardone et al., “Signal transduction by the polymeric immunoglobulin receptor suggests a role in regulation of receptor transcytosis.”The Journal of Cell Biology, 133(5):997-1005 (1996).
Cesare et al., “Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat.”Neuron, 23(3):617-24 (1999).
Chang, Q. and Tepperman, B.L., “The role of protein kinase C isozymes in TNF-alpha-induced cytotoxicity to a rat intestinal epithelial cell line.”,Am. J. Physiol Gastrointest Liver Physiol., 280(4):G572-83 (2001).
Chen, C. and Mochly-Rosen, D. (2001). “Opposing effects of delta and xi PKC in ethanol-induced cardioprotection.”J Mol Cell Cardiol. 33(3):581-5 (2001).
Chen et al., “Cardioprotection from ischemia by a brief exposure to physiological levels of ethanol: role of epsilon protein kinase C.”Proc Natl Acad Sci U S A, 96(22):12784-9 (1999).
Chen et al., “Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC.”Proc Natl Acad Sci U S A, 98(20):11114-9 (2001).
Chen et al., “Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7).”,Chemistry&Biology, 8(12):1123-9 (2001).
Csukai M. and Mochly-Rosen, D., “Molecular genetic approaches. II. Expression-interaction cloning.”,Methods in Molecular Biology, 88:133-9 (1998).
Csukai M. and Mochly-Rosen, D., “Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation.”,Pharmacological Research, 39(4):253-9 (1999).
Csukai et al., “The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase Cepsilon.”,The Journal of Biological Chemistry, 272(46):29200-6 (1997).
De et al., “Role of protein kinase C in control of ethanol-modulated beta-endorphin release from hypothalamic neurons in primary cultures.”,The Journal of Pharmacology and Experimental Therapeutics, 301(1):119-28 (2002).
Dempsey et al., “Protein kinase C isozymes and the regulation of diverse cell responses.”,Am J Physiol Lung Cell Mol Physiol., 279(3):L429-38 (2000).
Diamond et al., “The role of adenosine and adenosine transport in ethanol-induced cellular tolerance and dependence. Possible biologic and genetic markers of alcoholism.”,Annals N Y Academy of Sciences, 625:473-87 (1991).
Disatnik et al., “Distinct responses of protein kinase C isozymes to c-erbB-2 activation in SKBR-3 human breast carcinoma cells.”,Cell Growth&Differentiation, 5(8):873-80 (1994).
Disatnik et al., “Localization of protein kinase C isozymes in cardiac myocytes.”,Experimental Cell Research, 210(2):287-97 (1994).
Disatnik et al., “Sequential activation of individual PKC isozymes in integrin-mediated muscle cell spreading: a role for MARCKS in an integrin signaling pathway.”Journal of Cell Science, 115(Pt 10):2151-63 (2002).
Disatnik et al., “Phospholipase C-gamma 1 binding to intracellular receptors for activated protein kinase C.”,Proc Natl Acad Sci U S A, 91(2):559-63 (1994).
Disatnik et al., “Stimulus-dependent subcellular localization of activated protein kinase C; a study with acidic fibroblast growth factor and transforming growth factor-beta 1 in cardiac myocytes.”,J Mol Cell Cardiol, 27(11):2473-81 (1995).
Dorn, G. W. , and Mochly-Rosen, D., “Intracellular transport mechanisms of signal transducers.”Annu Rev Physiol. 64:407-29 (2002).
Dorn et al., “Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation.”Proc Natl Acad Sci U S A, 96(22):12798-803 (1999).
Efendiev et al., “PKC-βand PKC-ζ mediate opposing effects on proximal tubule Na+, K+-ATPase activity”,FEBS Letters, 456:45-48 (1999).
Flescher, E. and Rotem, R., “Protein kinase C epsilon mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells.”,Cellular Signaling, 14(1):37-43 (2002).
Garcia-Navarro et al., “Developmental expression of protein kinase C subspecies in rat brain-pituitary axis.”,Molecular and Cellular Endocrinology, 103(1-2):133-8 (1994).
Gray et al., “A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death.”,The Journal of Biological Chemistry, 272(49):30945-51 (1997).
Hayabuchi et al., “Angiotensin II inhibits and alters kinetics of voltage-gated K(+) channels of rat arterial smooth muscle.”,Am J Physiol Heart Circ Physiol, 281(6):H2480-9 (2001).
Hayabuchi et al., “Angiotensin II inhibits rat arterial KATP channels by inhibiting steady-state protein kinase A activity and activating protein kinase Ce.”,The Journal of Physiology, 530(Pt 2):193-205 (2001).
Heider et al., “PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism.”,Oncology Research, 14(10):475-82 (2004).
Hodge et al., “Supersensitivity to allosteric GABA(A) receptor modulators and alcohol in mice lacking PKCepsilon.”,Nature Neuroscience, 2(11):997-1002 (1999).
Hool, L. C., “Hypoxia increases the sensitivity of the L-type Ca(2+) current to beta-adrenergic receptor stimulation via

Affiliated with

Also associated with

Rating

Peptide inhibitors of protein kinase C does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide inhibitors of protein kinase C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitors of protein kinase C will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4227639